- Home
- KLG vs ELVN Comparison
KLG vs ELVN Comparison
Compare KLG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- ELVN
- Stock Information
- Founded
- KLG 2022
- ELVN 2016
- Country
- KLG United States
- ELVN United States
- Employees
- KLG N/A
- ELVN N/A
- Industry
- KLG Packaged Foods
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- KLG Consumer Staples
- ELVN Health Care
- Exchange
- KLG Nasdaq
- ELVN Nasdaq
- Market Cap
- KLG 1.4B
- ELVN 1.2B
- IPO Year
- KLG N/A
- ELVN 2020
- Fundamental
- Price
- KLG $23.13
- ELVN $21.20
- Analyst Decision
- KLG Hold
- ELVN Strong Buy
- Analyst Count
- KLG 7
- ELVN 5
- Target Price
- KLG $19.71
- ELVN $41.20
- AVG Volume (30 Days)
- KLG 4.0M
- ELVN 506.4K
- Earning Date
- KLG 08-05-2025
- ELVN 08-12-2025
- Dividend Yield
- KLG 2.85%
- ELVN N/A
- EPS Growth
- KLG N/A
- ELVN N/A
- EPS
- KLG 0.65
- ELVN N/A
- Revenue
- KLG $2,664,000,000.00
- ELVN N/A
- Revenue This Year
- KLG N/A
- ELVN N/A
- Revenue Next Year
- KLG N/A
- ELVN N/A
- P/E Ratio
- KLG $35.49
- ELVN N/A
- Revenue Growth
- KLG N/A
- ELVN N/A
- 52 Week Low
- KLG $14.80
- ELVN $13.30
- 52 Week High
- KLG $23.56
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- KLG 76.65
- ELVN 49.05
- Support Level
- KLG $16.35
- ELVN $21.25
- Resistance Level
- KLG $23.51
- ELVN $22.83
- Average True Range (ATR)
- KLG 0.30
- ELVN 1.51
- MACD
- KLG 0.13
- ELVN -0.10
- Stochastic Oscillator
- KLG 94.04
- ELVN 36.40
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands are now housed. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2024 base) in the US.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.